1378391-44-6

Basic information

• Product Name: Velpatasvir intermediate
• Synonyms: Velpatasvir intermediate;tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,4,5,11-tetrahydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate;Velpatasvir intermediate N-3;intermediate of Velpatasvir;(2S,4S)-TERT-BUTYL 2-(5-(2-((2S,5S)-1-((S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-5-METHYLPYRROLIDIN-2-YL)-1,4,5,11-TETRAHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOL-9-YL)-1H-IMIDAZOL-2-YL)-4-(METHOXYMETHYL)PYRROLIDINE-1-CARBOXYLATE;tert-butyl(2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,4,5,11-
• CAS NO: 1378391-44-6
• Molecular Formula: C44H55N7O7
• Molecular Weight: 793.95
• EINECS: 200-001-8
• Mol File: 1378391-44-6.mol

Chemical Properties

• Boiling Point: 1044.9±65.0 °C(Predicted)
• Appearance: /
• Density: 1.261±0.06 g/cm3(Predicted)
• PKA: 11.22±0.46(Predicted)
• CAS DataBase Reference: Velpatasvir intermediate(CAS DataBase Reference)
• NIST Chemistry Reference: Velpatasvir intermediate(1378391-44-6)
• EPA Substance Registry System: Velpatasvir intermediate(1378391-44-6)

Safety Data

• Hazardous Substances Data: 1378391-44-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Velpatasvir intermediate is used as a key synthetic component for the development of Velpatasvir, an antiviral medication. It is crucial for the creation of the drug's chemical structure, ensuring the medication's effectiveness in treating chronic hepatitis C virus infections.
Used in Antiviral Medication Synthesis:
Velpatasvir intermediate is employed as a critical building block in the synthesis of Velpatasvir, which targets the treatment of chronic hepatitis C. Its role in the formation of chemical bonds and structural components is vital for the drug's ability to combat the virus and support patient recovery.
Used in Quality Control and Testing:
In the production of Velpatasvir, the intermediate is also used as a subject for rigorous quality control and testing. This ensures that the final product meets the necessary safety and effectiveness standards, contributing to the overall reliability and trustworthiness of the medication.

Upstream product

• 1378388-37-4 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378393-23-7 C₁₅H₂₃NO₈ 
• 1194059-42-1 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(hydroxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378388-35-2 (3S,5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-pyrrolidine-3-carboxylic acid 
• 1378388-30-7 (2S,4S)-N-(tert-butyloxycarbonyl)pyrrolidine-2,4-dicarboxylic acid dimethyl ester 
• 487048-28-2 (2S,4S)-4-cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 1378388-16-9 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-39-9 (2S,4S)-1-tert-butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 

Downstream Products

• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1377604-63-1 methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl}carbamate 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1844064-96-5 (2S,4S)-2-[5-(2-{(2S,4S)-1-{N-(methoxycarbonyl)-L-valyl}-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromene[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine 

Relevant articles and documents

Preparation of velpatasvir and derivatives thereof

The invention relates to a preparation method of velpatasvir and derivatives thereof. Concretely, the preparation method provided by the invention comprises the step of preparing the velpatasvir and derivatives thereof (definitions of all the groups are described in the specification) by virtue of an intermediate compound shown in a formula. The preparation method provided by the invention has the advantages that byproducts are fewer, cost is low, and the preparation method is applicable to industrial production of velpatasvir. (The formula is described in the specification.).

CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.